Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorr

Showing results (1001-1010 of 1,229) with videos related to

Pageof 123
Sort By:
Cytometry. Part B, Clinical Cytometry|September 20, 2021
Biomarkers for the clinical development of antiviral therapiesTeresa I Ng, Patrick K Dorr, Preethi Krishnan, et al.
Investigational New Drugs|September 1, 2005
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancerRanjana Advani, Bert L Lum, George A Fisher, et al.
Cancer|January 13, 2004
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinomaRanjana Advani, Prema Peethambaram, Bert L Lum, et al.
AIDS Reviews|April 10, 2018
State of the Art in HIV Drug Resistance: Surveillance and Regional GapsCharles A Boucher, Marina R Bobkova, Chien-Ching Hung, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 30, 2014
Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitusTimothy P Reilly, Michael J Graziano, Evan B Janovitz, et al.
BMJ Open|January 17, 2014
Shared decision-making as a cost-containment strategy: US physician reactions from a cross-sectional surveyJon C Tilburt, Matthew K Wynia, Victor M Montori, et al.
Experimental Dermatology|January 29, 2024
Road-traffic-related air pollution contributes to skin barrier alteration and growth defect of sensory neuronsChristelle Le Gall-Lanotto, Anthony Verdin, Fabrice Cazier, et al.
Journal of Andrology|September 25, 2010
Association between serum testosterone and sex hormone-binding globulin and exercise capacity in men: results of the Study of Health in Pomerania (SHIP)Beate Koch, Sven Glaser, Christoph Schaper, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2009
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancerSteven J Cohen, Mark M Zalupski, Manuel R Modiano, et al.
The American Journal of Geriatric Pharmacotherapy|May 19, 2009
Potentially inappropriate medication prescribing in outpatient practices: prevalence and patient characteristics based on electronic health recordsMichael D Buck, Ashish Atreja, Cherie P Brunker, et al.
Pageof 123

Showing results (1001-1010 of 1,229) with videos related to

Sort By:
Pageof 123
Cytometry. Part B, Clinical Cytometry|September 20, 2021
Biomarkers for the clinical development of antiviral therapiesTeresa I Ng, Patrick K Dorr, Preethi Krishnan, et al.
Investigational New Drugs|September 1, 2005
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancerRanjana Advani, Bert L Lum, George A Fisher, et al.
Cancer|January 13, 2004
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinomaRanjana Advani, Prema Peethambaram, Bert L Lum, et al.
AIDS Reviews|April 10, 2018
State of the Art in HIV Drug Resistance: Surveillance and Regional GapsCharles A Boucher, Marina R Bobkova, Chien-Ching Hung, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 30, 2014
Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitusTimothy P Reilly, Michael J Graziano, Evan B Janovitz, et al.
BMJ Open|January 17, 2014
Shared decision-making as a cost-containment strategy: US physician reactions from a cross-sectional surveyJon C Tilburt, Matthew K Wynia, Victor M Montori, et al.
Experimental Dermatology|January 29, 2024
Road-traffic-related air pollution contributes to skin barrier alteration and growth defect of sensory neuronsChristelle Le Gall-Lanotto, Anthony Verdin, Fabrice Cazier, et al.
Journal of Andrology|September 25, 2010
Association between serum testosterone and sex hormone-binding globulin and exercise capacity in men: results of the Study of Health in Pomerania (SHIP)Beate Koch, Sven Glaser, Christoph Schaper, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2009
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancerSteven J Cohen, Mark M Zalupski, Manuel R Modiano, et al.
The American Journal of Geriatric Pharmacotherapy|May 19, 2009
Potentially inappropriate medication prescribing in outpatient practices: prevalence and patient characteristics based on electronic health recordsMichael D Buck, Ashish Atreja, Cherie P Brunker, et al.
Pageof 123